Pharsight

Veozah patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8871761 ASTELLAS NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Apr, 2031

(6 years from now)

US9422299 ASTELLAS Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Mar, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10836768 ASTELLAS N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Mar, 2034

(9 years from now)

US9987274 ASTELLAS N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Mar, 2034

(9 years from now)

Veozah is owned by Astellas.

Veozah contains Fezolinetant.

Veozah has a total of 4 drug patents out of which 0 drug patents have expired.

Veozah was authorised for market use on 12 May, 2023.

Veozah is available in tablet;oral dosage forms.

Veozah can be used as treatment of moderate to severe vasometer symptoms due to menopause, treatment of moderate to severe vasomotor symptoms due with menopause.

Drug patent challenges can be filed against Veozah from 13 May, 2027.

The generics of Veozah are possible to be released after 28 March, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 12, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FEZOLINETANT ingredient

NCE-1 date: 13 May, 2027

Market Authorisation Date: 12 May, 2023

Treatment: Treatment of moderate to severe vasomotor symptoms due with menopause; Treatment of moderate to severe vasometer symptoms due to menopause

Dosage: TABLET;ORAL

More Information on Dosage

VEOZAH family patents

Family Patents